Trend — Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion (Q2043) in Medicare, the United States

The full twelve-year services and payments series for this market — per-year values, with the FFS-enrollment denominator beside each.

The compound annual growth for Q2043 in the United States — endpoints exclude the introduction year; an Exclude 2020–21 view drops the pandemic years too.